Eledon Pharmaceuticals Inc (ELDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -22,811 | -16,011 | -14,065 | -13,116 | -5,655 |
| Depreciation Amortization | 183 | 2,049 | 11 | 22 | 35 |
| Income taxes - deferred | -404 | N/A | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | 1,094 | -1,958 | -65 |
| Other Working Capital | -180 | -1,203 | 618 | -2,475 | N/A |
| Other Operating Activity | 8,000 | 1,308 | 449 | 2,586 | 762 |
| Operating Cash Flow | $-15,212 | $-13,857 | $-11,893 | $-14,941 | $-4,923 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | 8 | 1 |
| Net Acquisitions | 11,035 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 23,250 | 0 |
| Investing Cash Flow | $11,035 | $N/A | $N/A | $23,258 | $1 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 2,930 |
| Common Stock Issued | 14,380 | 9,676 | 7,562 | 7,869 | N/A |
| Other Financing Activity | 95,201 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $109,581 | $9,676 | $7,562 | $7,869 | $2,930 |
| Beginning Cash Position | 8,791 | 12,972 | 17,303 | 1,117 | 3,109 |
| End Cash Position | 114,195 | 8,791 | 12,972 | 17,303 | 1,117 |
| Net Cash Flow | $105,404 | $-4,181 | $-4,331 | $16,186 | $-1,992 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,212 | -13,857 | -11,893 | -14,941 | -4,923 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -9 |
| Free Cash Flow | -15,212 | -13,857 | -11,893 | -14,941 | -4,932 |